Compare Inovio Pharmaceuticals Inc (INO) vs Starbucks Corp (SBUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Starbucks Corp — how do they compare? Inovio Pharmaceuticals Inc trades at $1.09 (market cap $89.27M), while Starbucks Corp trades at $104.71 (market cap $119.45B). The key difference: Starbucks Corp is far larger — about 1338.1× Inovio Pharmaceuticals Inc's market cap, and Starbucks Corp pays a 2.37% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | SBUX | |
|---|---|---|
Market Cap | $89.27M | $119.45B |
Sector | Health | Consumer Cyclical |
52-Week High | $2.87 | $108.37 |
52-Week Low | $1.05 | $78.46 |
Enterprise Value | $60.28M | $142.14B |
Volume | — | 7,493,833 |
Dividend Yield | — | 2.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $1.07, down 4.46% today, reflecting persistent bearish technical signals. The company shows minimal revenue of $65.34K (2025) with a net loss of $84.95M, resulting in a negative net margin of 130,000%. Despite beating recent EPS estimates, cash flow remains negative. Key near-term catalyst is the FDA's PDUFA decision on INO-3107 by October 30, 2026.
Outlook hinges on regulatory success for INO-3107; approval could drive significant upside, but failure poses substantial risk. High cash burn and lack of profitability underscore speculative nature. Analyst consensus is cautiously optimistic with 53% buy ratings, yet financial health remains precarious without near-term revenue growth.
Starbucks (SBUX) trades at $104.64, down 0.81% on the day, with a bullish technical outlook supported by moving averages. The stock shows mixed earnings performance, missing estimates in Q3 and Q4 2025 but beating in Q1 2026, while revenue growth remains steady. Recent news highlights cost-cutting initiatives, including a $400 million AI-driven software reduction plan, and strong channel development growth of 39% year-over-year in Q2 2026.
The investment outlook is cautiously optimistic, with a consensus price target of $108.86 offering modest upside. Key opportunities include margin expansion from cost efficiencies and dividend growth, but risks involve high valuation multiples, competitive pressures, and inconsistent earnings performance. Analyst sentiment is balanced with 47% buy and hold ratings each.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →
